CAR-T Cell Screening Service
InquiryCAR-T cell therapy is famous for fighting blood cancers, but the landscape is shifting rapidly. Researchers are now applying these living drugs to chronic metabolic conditions, particularly severe obesity and its associated comorbidities. Obesity involves systemic low-grade inflammation, adipose tissue remodeling, and the accumulation of senescent adipocyte progenitors. Developing effective chimeric antigen receptor (CAR) T cells for these non-oncology targets requires totally different design rules.
High-Throughput CAR-T Cell Screening Platform for Metabolic and Obesity Therapeutics
At Protheragen, we specialize exclusively in preclinical CAR-T cell screening services designed to accelerate your metabolic pipeline. We help you identify the most potent, specific, and stable CAR constructs before you move into expensive animal models. By evaluating antigen binding, signaling dynamics, and off-target reactivity against metabolic tissues early on, our platform minimizes downstream risks.
Core Technologies
Our screening infrastructure combines automated cellular analysis with advanced molecular profiling to handle the unique challenges of metabolic targeting.
We use specialized microfluidic arrays to screen hundreds of CAR construct variations simultaneously against target adipocytes or inflamed stromal cells.
Traditional suspension cultures don't work well for lipid-laden cells. We maintain specialized 3D mature adipocyte and stromal vascular fraction (SVF) co-cultures to replicate the architecture of obese fat tissue.
Using impedance-based labels and high-content imaging, we monitor cell-mediated lysis and adipocyte lipid release continuously over days, not just hours.
Metabolic CAR-T applications require careful balancing to avoid systemic cytokine storms. We track multiplex panels (including IL-6, TNF-ɑ, and IFN-γ) directly from co-culture supernatants to find the safest candidates.
Solution Scope
Our preclinical testing services cover the entire early-stage development funnel for metabolic engineering. We do not provide clinical services, allowing us to focus 100% of our engineering expertise on optimizing your upstream assets.
- Target Validation and Antigen Profiling
We assess how cleanly your chosen antigen is expressed on hypertrophic adipocytes, senescent adipose tissue macrophages, or fibro-adipogenic progenitors. This involves screening against expansive primary human and rodent cell panels to profile baseline expression levels and reduce downstream off-target cross-reactivity.
- CAR Library Formatting and Screening
We screen variations in hinge regions, transmembrane domains, and costimulatory domains (such as 4-1BB or CD28) to determine which combinations survive best in the tricky, immunosuppressive microenvironment of inflamed adipose tissue.
- In Vitro Metabolic Potency Profiling
We do not just look at cell death. For obesity applications, we track metabolic readouts like lipolysis rates, glycerol release, gene expression changes in surviving cells (such as UCP1 up-regulation), and alterations in lipid storage dynamics following CAR-T interaction.
- Safety and Cross-Reactivity Panel Testing
To prevent severe off-target toxicities, your candidate cells are screened against vital non-target tissue profiles, including healthy vascular endothelial cells, hepatocytes, and skeletal muscle tissue. This provides an early laboratory safety margin before initiating in vivo rodent work.
Partner with Protheragen to map out a customized preclinical screening program.
Workflow
To streamline our discovery pipeline, Protheragen utilizes an automated, five-step circular workflow that transitions seamlessly from initial gene synthesis to final lead selection.
Fields of Application
Our screening capabilities support a variety of innovative therapeutic strategies aiming to manage obesity and metabolic syndrome through immune cell engineering.
- Senolytic CAR-T Development
Screening constructs engineered to target and eliminate senescent adipose tissue cells that drive chronic metabolic inflammation and insulin resistance. - Fibro-Adipogenic Progenitor Modulation
Evaluating candidates that target pathogenic fibrotic cells in expanding fat tissue, allowing for healthier lipid storage and reduced visceral fat accumulation. - Adipokine Receptor Targeting
Optimizing CAR configurations designed to selectively modulate specific subsets of overexpanded mature adipocytes to rebalance systemic energy expenditure.
Advantages
Partnering with Protheragen gives you access to a platform explicitly optimized for metabolic and inflammatory biology rather than oncological systems.
Adipose-Specific Specialty Platform
Our custom-designed adipocyte testing platforms simulate authentic tissue environments, which dramatically improves the physiological relevance of your early screening data.
Rapid Turnaround Timelines
Our automated, parallelized processing workflows cut construct evaluation timelines down significantly. This high-throughput architecture reduces early lead selection phases by up to 40% compared to traditional manual bench workflows.
Deep Metabolic Characterization
We provide granular insights into how engineered immune cells alter the surrounding metabolic environment. This means you receive clear data on cytokine profiles, lipid mobilization markers, and target cell survival curves rather than simple, binary live/dead readouts.
Rigorous Preclinical Quality Standards
Every single screening assay run includes comprehensive internal controls and standardized validation steps. This highly reproducible data generation ensures your transition to subsequent animal proof-of-concept models is backed by solid, auditable laboratory evidence.
Submit a project inquiry to discuss your specific target constructs.
Customer Review
Accelerating Candidate Selection Through Specialized Adipocyte Co-Culture Validation
"Working with Protheragen changed how we approached our senolytic CAR-T project. Their specialized adipocyte co-culture models gave us an accurate view of construct performance under real metabolic stress, helping us cut down our candidate list from twenty down to our top two leads much faster than we anticipated."
Dr. A. T., Director of Biologics Discovery
Translating Complex Metabolic Tissue Dynamics into High-Resolution Preclinical Data Packages
"Developing cellular models for non-oncology indications is always challenging because standard protocols rarely fit. Protheragen adapted their validation assays to include lipid-stress conditions, giving us the exact data we needed to move our program forward. We continue to rely on them for our ongoing receptor optimization work."
Dr. E. R., Head of R&D
Frequently Asked Questions
-
Why do we need a specialized CAR-T screening service for obesity instead of standard oncology screening?
Oncology CAR-T screening typically looks for rapid, high-affinity killing of tumor cells in suspension or simple monolayers. Obesity applications require fine-tuned kinetics, survival in highly lipophilic environments, and minimal systemic inflammatory triggers. Our platform is customized specifically to measure these subtle metabolic behaviors.
-
Does Protheragen offer any clinical manufacturing or human testing services?
No, we focus exclusively on the preclinical research stage. Our core expertise lies in high-throughput construct validation, in vitro functional assays, and early lead optimization. This concentration allows us to provide deep, specialized technical insight to advance your discovery programs.
-
What kind of target cell lines do you use during the screening process?
We utilize a mixture of primary human preadipocytes differentiated in-house, rodent stromal vascular fractions (SVF), and specialized continuous adipocyte cell models. This diversity ensures your constructs are fully evaluated across both human target profiles and relevant animal cross-reactive targets.
-
How do you evaluate the risk of systemic cytokine release syndrome (CRS) in an in vitro setup?
While no lab assay perfectly replicates a whole organism, we use highly sensitive multiplexed bead arrays to measure the exact secretion rates of core inflammatory cytokines over extended co-culture periods. This helps you filter out hyper-reactive constructs early.
-
Can we supply our own unique CAR-T viral vectors or constructs for testing?
Yes, absolutely. We can either accept your premade lentiviral plasmids/particles or utilize our internal molecular biology suite to synthesize and assemble specific vector configurations based on your digital sequence files.
-
What metrics are used to define a successful 'hit' during your high-throughput screening?
We look at a balanced index score combining high target-specific lysis, low baseline cytokine production, minimal off-target reactivity against healthy tissue panels, and sustained T-cell viability under metabolic stress conditions.
-
How do you handle the unique challenges of culturing mature, floating adipocytes?
We utilize specialized matrix-embedding techniques and inverted cell culture configurations that keep lipid-laden, buoyant adipocytes in stable, reproducible contact with the engineered T cells throughout the testing period.
-
What is the typical timeframe required to complete a multi-construct screening project?
Depending on the size of your candidate library and the specific assay configurations chosen, most standard discovery projects run between 4 and 8 weeks from sequence finalization to the delivery of the complete data analysis package.
-
How is our proprietary sequence data and intellectual property protected at Protheragen?
We implement strict operational data segregation and formal non-disclosure protections for every client. Your structural sequences and screening readouts remain fully confidential and are never utilized for internal projects or shared with third parties.
Contact Us
Developing effective cell therapies for complex metabolic disorders like obesity demands specialized, rigorous preclinical validation. Protheragen delivers the advanced high-throughput screening tools, tailored tissue environments, and deep scientific focus necessary to transform your early-stage constructs into highly optimized therapeutic candidates. Welcome to Contact Protheragen to receive a detailed proposal and pricing for your upcoming project.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.